Key result
CIED-detected subclinical AF links to higher thromboembolic risk, but optimal anticoagulation remains unresolved.
Why the study?
The risk of thromboembolic events varies between patients with subclinical atrial fibrillation (SCAF) and clinically overt AF, leaving the role of anticoagulant therapy in SCAF unresolved.
Does anticoagulant therapy prevent thromboembolic events in patients with cardiac implantable electronic devices and subclinical atrial fibrillation?
Population
Patients with CIEDs and subclinical atrial fibrillation
Design
Review
Authors
Loading...
Anticoagulation decisions for CIED-detected subclinical AF should remain individualized; leaves open optimal thresholds pending dedicated RCTs.
Does anticoagulant therapy prevent thromboembolic events in patients with cardiac implantable electronic devices and subclinical atrial fibrillation?
This review highlights that while subclinical AF detected by CIEDs increases thromboembolic risk, routine anticoagulation is currently only considered for longer episodes (e.g., >24 hours) or high-risk patients, pending definitive trial data.
Razina et al. (2023) conducted a review in Subclinical atrial fibrillation in patients with cardiac implantable electronic devices. Anticoagulant therapy was evaluated. Subclinical atrial fibrillation detected by cardiac implantable electronic devices is associated with an increased risk of thromboembolic events, but the optimal strategy for anticoagulant therapy remains unresolved.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: